



asx release

13 JULY 2020

Non-Renounceable Rights Issue – Despatch of Prospectus and Entitlement and Acceptance Form

Cann Global Ltd (ASX:CGB) (“Cann Global” or “Company”) confirms that the Prospectus and accompanying Entitlement and Acceptance forms have been despatched to Eligible Shareholders today for the fully underwritten pro rata non- renounceable Rights Issue of one new share (**New Share**) for every 4 existing shares held at the record date of 9 July 2020 (**Record Date**) at a price of \$0.005 per New Share, together with 1 for 2 free attaching option (**New Options**).

The maximum number of New Shares which will be issued under the Entitlement Offer is 847,497,261 raising up to approximately \$4.24 million (before expenses, based on the current capital structure of the Company). New Options will have an exercise price of 1.2 cents exercisable on or before 31 January 2022.

As previously announced on 3 July 2020, the key dates for the Rights Issue are outlined in the timetable below.

Entitlement Offer Timetable

EVENT	DATE
Announcement of Rights Issue	Friday 3 July 2020
Ex-date	Wednesday 8 July 2020
Record date for determining Entitlements (5.00pm EST)	Thursday 9 July 2020
Prospectus despatched, Entitlement Offer opens	Monday 13 July 2020
Last day to extend the Closing Date	Monday 20 July 2020
Entitlement Offer closes	Thursday 23 July 2020
Deferred settlement trading occurs	Friday 24 July 2020
Announcement of results of issue	Tuesday 28 July 2020
Issue of New Shares, deferred settlement ends	Thursday 30 July 2020
Trading of New Shares commences	Friday 31 July 2020

* The Directors may extend the Closing Date by giving at least three Business Days’ notice to ASX prior to the Closing Date. As such the date the Shares are expected to commence trading on ASX may vary.

Further information

About Cann Global

Cann Global Limited (ASX:CGB) is a driving force in the hemp and medical Cannabis industries. Our strength comes from our team's core competencies and expertise, and our solid and strategic partnerships with experts in Australia, USA, Israel, Asia, Africa and Canada. We are working under the relevant legislation to ensure that the future in Medical Cannabis and Natural Foods will allow medical practitioners, patients, and consumers to gain access to the right information, as well as the safest, most effective and sustainable products.

Authority and Contact Details

This announcement has been authorised for release by Sholom Feldman, Managing Director.

For further details, contact Sholom Feldman, Managing Director, on +61 (0)2 8379 1832, or via email sfeldman@canngloballimited.com